Current understanding and treatment of intra-amniotic infection with Ureaplasma spp.
Adult
Amniotic Fluid
/ microbiology
Anti-Bacterial Agents
/ therapeutic use
Azithromycin
/ therapeutic use
Chorioamnionitis
/ drug therapy
Female
Humans
Infant, Newborn
Infant, Newborn, Diseases
/ microbiology
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Premature Birth
/ microbiology
Ureaplasma
/ drug effects
Ureaplasma Infections
/ drug therapy
Virulence
Ureaplasma
anti-bacterial agent
antibiotic resistance
chorioamnionitis
preterm birth
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
13
05
2019
accepted:
23
06
2019
pubmed:
18
7
2019
medline:
11
2
2020
entrez:
18
7
2019
Statut:
ppublish
Résumé
Considerable evidence has shown that intra-amniotic infection with Ureaplasma spp. increases the risk of chorioamnionitis and preterm labor. Ureaplasma spp. are among the smallest organisms, and their isolation is uncommon in routine clinical practice because of their size and high auxotrophy. Although Ureaplasma spp. have been reported as causative agents of preterm birth, they also have a high incidence in vaginal swabs collected from healthy reproductive-age women; this has led to questions on the virulence of Ureaplasma spp. and to them being considered as harmless commensal bacteria. Therefore, many efforts have been made to clarify the pathogenicity of Ureaplasma spp. at the molecular level. Ureaplasma spp. are surrounded by lipoproteins, including multiple-banded antigen. Both multiple-banded antigen and its derivative, that is, the synthetic lipopeptide, UPM-1, induce an inflammatory response in a preterm mice model, which was adequate to cause preterm birth or stillbirth. In this review, we present an overview of the virulence mechanisms of Ureaplasma spp. and treatment of ureaplasma infection during pregnancy to prevent possible serious sequelae in infants. In addition, relevant mechanisms underlying antibiotic resistance in Ureaplasma spp. are discussed. Ureaplasma spp. are naturally resistant against β-lactam antibiotics because of the lack of a cell wall. Azithromycin is one of the effective agents that can control intrauterine ureaplasma infection. In fact, macrolide- and fluoroquinolone-resistant isolates of Ureaplasma spp. have already been observed in perinatal practice in Japan.
Substances chimiques
Anti-Bacterial Agents
0
Azithromycin
83905-01-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1796-1808Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP17fk0108210
Organisme : Japan Society for the Promotion of Science
ID : JP17H04237
Organisme : Biomedical Engineering Research from Nakatani Foundation, for Advanced of Measuring Technologies in Biomedical Engineering
Informations de copyright
© 2019 Japan Society of Obstetrics and Gynecology.
Références
World Health Organization. Preterm birth [Internet]. 2018. [Cited 27 Jan 2019]. Available from URL: https://www.who.int/en/news-room/fact-sheets/detail/preterm-birth.
Taylor-Robinson D, Lamont RF. Mycoplasmas in pregnancy. Br J Obstet Gynaecol 2010; 118: 164-174.
Romero R, Espinoza K, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. Semin Reprod Med 2011; 38: 385-406.
Romero R, Gomez R, Chaiworapongsa T, Conoscenti G, Kim JC, Kim YM. The role of infection in preterm labour and delivery. Paediatr Perinat Epidemiol 2001; 15: 41-56.
Digiulio DB. Diversity of microbes in amniotic fluid. Semin Fetal Neonatal Med 2012; 17: 2-11.
Bebear CM, Bebear C. Molecular biology and pathogenicity of mycoplasmas. In: Razin S, Herrman R (eds). Vol. 91, Antimycoplasmal Agents. New York, NY: Kluwer Academic Publishers, 2002; 545-566.
Shepard MC, Lunceford CD, Ford DK et al. Ureaplasma urealyticum gen. no., sp. nov.: proposed nomenclature for the human T (T-Strain) mycoplasmas. Int J Syst Bacteriol 1974; 24: 160-171.
Gomez R, Romero R, Nien JK et al. A short cervix in women with preterm labor and intact membranes: A risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol 2005; 192: 678-689.
Kemp MW, Miura Y, Payne MS et al. Repeated maternal intramuscular or intraamniotic erythromycin incompletely resolves intrauterine Ureaplasma parvum infection in a sheep model of pregnancy. Am J Obstet Gynecol 2014; 211: 134.e1-134.e9.
Yoon BH, Romero R, Kim M et al. Clinical implications of detection of Ureaplasma urealyticum in the amniotic cavity with the polymerase chain reaction. Am J Obstet Gynecol 2000; 183: 1130-1137.
Yoon BH, Romero R, Lim J, Shim S. The clinical significance of detecting Ureaplasma urealyticum by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. Am J Obstet Gynecol 2003; 189: 919-924.
Namba F, Hasegawa T, Nakayama M et al. Placental features of chorioamnionitis colonized with Ureaplasma species in preterm delivery. Pediatr Res 2010; 67: 166-172.
Smorgick N, Frenkel E, Zaidenstein R, Lazarovitch T, Sherman DJ. Antibiotic treatment of intra-amniotic infection with Ureaplasma urealyticum: A case report and literature review. Fetal Diagn Ther 2007; 22: 90-93.
Dando SJ, Nitsos I, Newnham JP, Jobe AH, Moss TJM, Knox CL. Maternal administration of erythromycin fails to eradicate intrauterine Ureaplasma infection in an ovine model. Biol Reprod 2010; 83: 616-622.
Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179: 194-202.
Uchida K, Nakahira K, Mimura K et al. Effects of Ureaplasma parvum lipoprotein multiple-banded antigen on pregnancy outcome in mice. J Reprod Immunol 2013; 100: 118-127.
Shimizu T, Kida Y, Kuwano K. Ureaplasma parvum lipoproteins, including MB antigen, activate NF-κB through TLR1, TLR2 and TLR6. Microbiology 2008; 154: 1318-1325.
Knox CL, Dando SJ, Nitsos I et al. The severity of chorioamnionitis in pregnant sheep is associated with in vivo variation of the surface-exposed multiple-banded antigen/gene of Ureaplasma parvum. Biol Reprod 2010; 83: 415-426.
Sweeney EL, Kallapur SG, Meawad S et al. Ureaplasma species multiple banded antigen (MBA) variation is associated with the severity of inflammation in vivo and in vitro in human placentae. Front Cell Infect Microbiol 2017; 7: 123.
Dando SJ, Nitsos I, Kallapur SG et al. The role of the multiple banded antigen of Ureaplasma parvum in intra-amniotic infection: Major virulence factor or decoy? PLoS One 2012; 7: e29856.
Harada K, Tanaka H, Komori S et al. Vaginal infection with Ureaplasma urealyticum accounts for preterm delivery via induction of inflammatory responses. Microbiol Immunol 2008; 52: 297-304.
Biernat-Sudolska M, Bilska-Wilkosz A, Rojek-Zakrzewska D, Zawilińska B, Kosz-Vnenchak M. Evaluation of urease activity by the human Ureaplasma species. Folia Biol 2017; 65: 143-147.
Spooner RK, Russell WC, Thirkell D. Characterization of the immunoglobulin A protease of Ureaplasma urealyticum. Infect Immun 1992; 60: 2544-2546.
Buzinhani M, Yamaguti M, Oliveira RC et al. Invasion of Ureaplasma diversum in bovine spermatozoids. BMC Res Notes 2011; 4: 455.
Santos-Junior MN, Rezende IS, Souza CLS et al. Ureaplasma diversum and its membrane-associated lipoproteins activate inflammatory genes through the NF-κB pathway via toll-like receptor 4. Front Microbiol 2018; 9: 1-14.
Nishiumi F, Ogawa M, Nakura Y et al. Intracellular fate of Ureaplasma parvum entrapped by host cellular autophagy. Microbiology 2017; 6: 1-15.
Kacerovsky M, Pliskova L, Menon R et al. Microbial load of umbilical cord blood Ureaplasma species and Mycoplasma hominis in preterm prelabor rupture of membranes. J Matern Neonatal Med 2014; 27: 1627-1632.
Oh KJ, Hong J-S, Roberto R, Bo HY. The earlier the gestational age in preterm PROM, the greater the intensity of the intra-amniotic inflammatory response in patients with Ureaplasma infections. J Perinat Med 2019; 47: 516-527.https://doi.org/10.1515/jpm-2019-0003
Rittenschober-Böhm J, Waldhoer T, Schulz SM et al. First trimester vaginal Ureaplasma biovar colonization and preterm birth: Results of a prospective multicenter study. Neonatology 2017; 113: 1-6.
Cox C, Saxena N, Watt AP et al. The common vaginal commensal bacterium Ureaplasma parvum is associated with chorioamnionitis in extreme preterm labor. J Matern Neonatal Med 2016; 29: 3646-3651.
Olomu IN, Hecht JL, Onderdonk AO, Allred EN, Leviton A. Perinatal correlates of Ureaplasma urealyticum in placenta parenchyma of singleton pregnancies that end before 28 weeks of gestation. Pediatrics 2009; 123: 1329-1336.
Kataoka S, Yamada T, Chou K et al. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J Clin Microbiol 2006; 44: 51-55.
Payne MS, Ireland DJ, Watts R et al. Ureaplasma parvum genotype, combined vaginal colonisation with Candida albicans, and spontaneous preterm birth in an Australian cohort of pregnant women. BMC Pregnancy Childbirth 2016; 16: 1-13.
DiGiulio DB, Callahan BJ, McMurdie PJ et al. Temporal and spatial variation of the human microbiota during pregnancy. Proc Natl Acad Sci 2015; 112: 11060-11065.
Urushiyama D, Suda W, Ohnishi E et al. Microbiome profile of the amniotic fluid as a predictive biomarker of perinatal outcome. Sci Rep 2017; 7: 1-10.
Prince AL, Ma J, Kannan PS et al. The placental membrane microbiome is altered among subjects with spontaneous preterm birth with and without chorioamnionitis. Am J Obstet Gynecol 2016; 214: 627e1-627e16.
Fuwa K, Seki M, Hirata Y et al. Rapid and simple detection of Ureaplasma species from vaginal swab samples using a loop-mediated isothermal amplification method. Am J Reprod Immunol 2018; 79: e12771.
Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous. Obstet Gynecol Surv 2007; 110: 687-694.
American College of Obstetricians and Gynecologists. Intrapartum management of intraamniotic infection. Committee Opinion No. 712. Obstet Gynecol 2017; 130: e95-e101.
American College of Obstetricians and Gynecologists. Use of prophylactic antibiotics in labor and delivery. ACOG Practice Bulletin No. 199. Obstet Gynecol 2018; 132: e103-e119.
Center for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. MMWR 2010; 59: 4.
Katz B, Schelonka RL, Waites KB. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18: 757-789.
Beeton ML, Chalker VJ, Jones LC, Maxwell NC, Spiller OB. Antibiotic resistance among clinical Ureaplasma isolates recovered from neonates in England and Wales between 2007 and 2013. Antimicrob Agents Chemother 2016; 60: 52-56.
Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol 2016; 30: 1650-1656.
Grigsby PL, Novy MJ, Sadowsky DW et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol 2012; 207: 475.e1-475.e14.
Romero R, Hagay Z, Nores J, Sepulveda W. Eradication of Ureaplasma urealyticum from the amniotic fluid with transplacental antibiotic treatment. Am J Obstet Gynecol 1992; 166: 618-620.
Mazzei T, Mini A, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993; 21 (Supplement): 1-9.
Donders GGG, Ruban K, Bellen G, Petricevic L. Mycoplasma/Ureaplasma infection in pregnancy: To screen or not to screen. J Perinat Med 2017; 45: 505-515.
Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol 2013; 208: 221.e1-221.e8.
Berard A, Sheehy O, Zhao J-P, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: A population-based study. Pharmacoepidemiol Drug Saf 2015; 24: 1241-1248.
Dinur AB, Koren G, Matok I et al. Fetal safety of macrolides. Antimicrob Agents Chemother 2013; 57: 3307-3311.
Mazor M, Chaim W, Horowitz S, Leiberman JR, Glezerman M. Successful treatment of preterm labour by eradication of Ureaplasma urealyticum with erythromycin. Arch Gynecol Obstet 1993; 253: 215-218.
Antsaklis A, Daskalakis G, Michalas S, Aravantinos D. Erythromycin treatment for subclinical Ureaplasma urealyticum infection in preterm labor. Fetal Diagn Ther 1997; 12: 89-92.
Kenyon SL, Taylor DJ, Tanow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: The ORACLE I randomised trial. Lancet 2001; 357: 979-988.
Redelinghuys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM. Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in pregnant women. BMC Infect Dis 2014; 14: 171.
Krausse R, Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect 2010; 16: 1649-1655.
Acosta EP, Grigsby PL, Larson KB et al. Transplacental transfer of azithromycin and its use for eradicating intra-amniotic Ureaplasma infection in a primate model. J Infect Dis 2014; 209: 898-904.
Khosropour CM, Manhart LE, Gillespie CW et al. Efficacy of standard therapies against Ureaplasma species and persistence among men with nongonococcal urethritis enrolled in a randomised controlled trial. Sex Transm Infect 2015; 91: 308-313.
Lee SJ, Ahn JW, Lee JY, Lee SH, Roh HJ, Kwon YS. Maternal azithromycin administration eradicates intra-amniotic Ureaplasma infection: The first human case report. J Obstet Gynaecol (Lahore) 2016; 36: 259-260.
Tanaka S, Tsumura K, Nakura Y et al. New antibiotic regimen for preterm premature rupture of membrane reduces the incidence of bronchopulmonary dysplasia. J Obstet Gynaecol Res 2019; 45: 967-973.
Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: A systematic review and meta-analysis. Neonatology 2014; 106: 337-347.
Xie X, Zhang J. Trends in the rates of resistance of Ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients. FEMS Microbiol Lett 2006; 259: 181-186.
Kadhim A-k G. Susceptibility and antimicrobial resistance of genital Ureaplasma parvum. Nano Biomed Eng 2017; 9: 236-241.
Beeton ML, Spiller OB. Antibiotic resistance among Ureaplasma spp. isolates: Cause for concern? J Antimicrob Chemother 2017; 72: 330-337.
Koh E, Kim S, Kim I-S, Maeng K-Y, Lee S-A. Antimicrobial susceptibilities of Ureaplasma urealyticum and Mycoplasma hominis in pregnant women. Korean J Clin Microbiol 2009; 12: 159-162.
Abdel Rahman SM, Hassan RA, Sakna NA. Antimicrobial susceptibility pattern of genital Mycoplasmas among a group of pregnant women. Alexandria J Med 2016; 52: 353-358.
Lee MY, Kim MH, Lee WI, Kang SY, Jeon YL. Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Yonsei Med J 2016; 57: 1271-1275.
Witt A, Sommer EM, Cichna M et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003; 188: 816-819.
De Francesco MA, Caracciolo S, Bonfanti C, Manca N. Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J Infect Chemother 2013; 19: 621-627.
Longdoh NA, Gregory HE, Djeumako WA, Nguedia AJ, Francois M, Tebit KE. The occurrence and antimicrobial susceptibility patterns of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women in three district hospitals in Douala Cameroon. J Adv Med Med Res 2018; 27: 1-11.
Kenny GE, Cartwright FD. Dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-2608.
Bayraktar MR, Ozerol IH, Gucluer N, Celik O. Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Int J Infect Dis 2010; 14: e90-e95.
Kayem G, Doloy A, Schmitz T et al. Antibiotics for amniotic-fluid colonization by Ureaplasma and/or Mycoplasma spp. To prevent preterm birth: A randomized trial. PLoS One 2018; 13: e0206290.
Lincosamides GD. In: Finch R, Greenwood D, Norrby R, Whitley RJ (eds). Antibiotic and Chemotherapy, 9th edn. Philadelphia, PA: W.B. Saunders, 2010; 272-275.
Vouga M, Greub G, Prod'hom G et al. Treatment of genital mycoplasma in colonized pregnant women in late pregnancy is associated with a lower rate of premature labour and neonatal complications. Clin Microbiol Infect 2014; 20: 1074-1079.
American College of Obstetricians and Gynecologists. Prevention of early-onset group B streptococcal disease in newborns. Committee Opinion No. 485. Obstet Gynecol 2011; 117: 1019-1027.
Ziv A, Masarwa R, Perlman A, Ziv D, Matok I. Pregnancy outcomes following exposure to quinolone antibiotics-A systematic-review and meta-analysis. Pharm Res 2018; 35: 109.
Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: A meta-analysis. BJOG An Int J Obstet Gynaecol 2018; 125: 1069-1076.
Mushtaq A. Solithromycin to treat community-acquired pneumonia? Lancet Respir Med 2015; 3: 429.
Furfaro LL, Spiller OB, Keelan JA, Payne MS. In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin. Int J Antimicrob Agents 2015; 46: 319-324.
Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009; 53: 2139-2141.
Keelan JA, Pugazhenthi K. Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta. Placenta 2014; 35: 1043-1048.
Keelan JA, Kemp MW, Payne MS et al. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrob Agents Chemother 2014; 58: 447-454.
Miura Y, Payne MS, Keelan JA et al. Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrob Agents Chemother 2014; 58: 5413-5420.
Keelan JA, Payne MS, Kemp MW, Ireland DJ, Newnham JP. A new, potent, and placenta-permeable macrolide antibiotic, solithromycin, for the prevention and treatment of bacterial infections in pregnancy. Front Immunol 2016; 7: 111.
Lee JH, Romero R, Kim SM et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. J Matern Neonatal Med 2016; 29: 707-720.
Lee JH, Romero R, Kim SM, Chaemsaithong P, Yoon BH. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. J Matern Neonatal Med 2016; 29: 2727-2737.
Palu G, Valisena S, Barile MF, Meloni GA. Mechanisms of macrolide resistance in Ureaplasma urealyticum: A study on collection on clinical strains. Eur J Epidemiol 1989; 5: 146-153.
Dongya M, Wencheng X, Xiaobo M, Lu W. Transition mutations in 23S rRNA account for acquired resistance to macrolides in Ureaplasma urealyticum. Microb Drug Resist 2008; 14: 183-186.
Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44: 2118-2125.
Zaman S, Fitzpatrick M, Lindahl L, Zengel J. Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli. Mol Microbiol 2007; 66: 1039-1050.
Reinert RR, Wild A, Appelbaum P, Rudolf L, Cil MT, Al-Lahham A. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob Agents Chemother 2003; 47: 2319-2322.
Bébéar CM, Renaudin H, Charron A, Clerc M, Pereyre S, Bébéar C. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob Agents Chemother 2003; 47: 3323-3325.
Song J, Qiao Y, Kong Y et al. Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species. J Med Microbiol 2015; 64: 1315-1320.
Piccinelli G, Gargiulo F, Biscaro V, Caccuri F, Caruso A, De Francesco MA. Analysis of mutations in DNA gyrase and topoisomerase IV of Ureaplasma urealyticum and Ureaplasma parvum serovars resistant to fluoroquinolones. Infect Genet Evol 2017; 47: 64-67.
Kawai Y, Nakura Y, Wakimoto T et al. In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan. Antimicrob Agents Chemother 2015; 59: 2358-2364.
Feng C, Huang Y, Yu Y et al. Effects on quinolone resistance due to the biofilm formation activity in Ureaplasma urealyticum. Turk J Med Sci 2015; 45: 55-59.
Soroka AE, Akopyan TA, Taraskina AE, Baitsur MV, Savicheva AM, Govorun VM. Allelic polymorphism of the tet(M) determinant in Mycoplasma hominis and Ureaplasma urealyticum clinical isolates resistant to tetracyclines. Russ J Genet 2002; 38: 1236-1241.
Mardassi BBA, Aissani N, Moalla I, Dhahri D, Dridi A, Mlik B. Evidence for the predominance of a single tet(M) gene sequence type in tetracycline-resistant Ureaplasma parvum and Mycoplasma hominis isolates from Tunisian patients. J Med Microbiol 2012; 61: 1254-1261.
Govender S, Chalkley L. Tetracycline resistance genes of ureaplasmas. South Afr J Epidemiol Infect 2012; 27: 19-23.
Govender S, Gqunta K, Roux M, De Villiers B, Chalkley LJ. Antibiotic susceptibilities and resistance genes of Ureaplasma parvum isolated in South Africa. J Antimicrob Chemother 2012; 67: 2821-2824.
Mendling W. Microbiota of the human body. In: Shwiertz A (ed). Advances in Experimental Medicine and Biology. Switzerland: Springer International Publishing, 2016; 83-93.
Stafford GP, Parker JL, Amabebe E et al. Spontaneous preterm birth is associated with differential expression of vaginal metabolites by lactobacilli-dominated microflora. Front Physiol 2017; 8: 615.
Tabatabaei N, Eren A, Barreiro L et al. Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: A case-control study. BJOG An Int J Obstet Gynaecol 2019; 126: 349-358.
Daniele M, Ruiz F, Pascual L, Barberis L. Ureaplasma urealyticum and Mycoplasma hominis sensitivity to bacteriocins produced by two Lactobacilli strains. Curr Microbiol 2011; 63: 360-365.
Ullmann U, Schubert S, Krausse R. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999; 43 (SUPPL. C): 33-36.
Duffy LB, Crabb D, Searcey K, Kempf MC. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother 2000; 45 (Suppl 1): 29-33.
Valentine-King MA, Brown MB. Antibacterial resistance in Ureaplasma species and Mycoplasma hominis isolates from urine cultures in college-aged females. Antimicrob Agents Chemother 2017; 61: e01104-e01117.
Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother 2011; 23: 77-79.
Bébéar CM, de Barbeyrac B, Pereyre S, Renaudin H, Clerc M, Bébéar C. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801-805.
Fernández J, Karau MJ, Cunningham SA, Greenwood-Quaintance KE, Patel R. Antimicrobial susceptibility and clonality of clinical Ureaplasma isolates in the United States. Antimicrob Agents Chemother 2016; 60: 4793-4798.
Lucke K, Kuster SP, Bertea M, Ruef C, Bloemberg GV. A deep sternal wound infection caused by Ureaplasma urealyticum. J Med Microbiol 2010; 59: 1254-1256.